Abstract
The global therapeutic botulinum toxin (BTX) market, including the US, Europe
(France, Germany, Italy, Spain, and the UK), and Japan, exceeded $600 million
in 2008
Through 2013, growth will be fueled by the approval of new treatment
indications of BTX, which will significantly expand procedure volumes and
bolster unit demand
| 
View Cart
